{"doi":"10.53350/pjmhs22161683","title":"Comparison of Clinical Effectiveness of Atorvastatin and Rosuvastatin Among High-Risk Patients with Dyslipidaemia","abstract":"<jats:p>Aim: The aim of this analysis was to compare the effectiveness of rosuvastatin in lowering cholesterol with that of atorvastatin in patients at high risk of dyslipidaemia. Place and Duration: In the Medicine department of Islam Medical College and Teaching Hospital Sialkot for six months duration from June 2021 to November 2021. Methods: This randomized, open-label study enrolled 90 patients with high-risk dyslipidaemia and diagnosed according to the international guidelines for the prevention of adult dyslipidaemia. These patients were randomized to rosuvastatin and atorvastatin to receive rosuvastatin 20 mg / day and atorvastatin 20 mg / day, respectively, for three months. In both groups, the efficacy of atorvastatin and rosuvastatin on the concentration of LDL-C, HDL-C, total cholesterol (TC) and triglycerides (TG) was assessed. In addition, the rates of achieving LDL-C or TC target levels were assessed in both groups. Results: Rosuvastatin caused a significantly greater reduction of LDL-C (43.2% and 38.1%, p &lt;0.05) and TC (34.8% Vs 28.1%, p &lt;0.05) than Atorvastatin. In addition, the percentage of subjects attaining the recommended target TC and LDL-C levels was higher in the group of rosuvastatin as compared to the atorvastatin group. Conclusions: In patients at high risk of hyperlipidemia, rosuvastatin has high efficacy in decreasing lipids than atorvastatin. Keywords: rosuvastatin, atorvastatin, dyslipidaemia, high-density lipoprotein, triglycerides.</jats:p>","journal":"Pakistan Journal of Medical and Health Sciences","year":2022,"id":640509,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1664693,"name":"Hammad Ur Rehman Bhatti","orcid":null,"position":1,"is_corresponding":false},{"id":1664694,"name":"Ahsan Ayub","orcid":null,"position":2,"is_corresponding":false},{"id":1664692,"name":"Muhammad Ayyaz","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparison of Clinical Effectiveness of Atorvastatin and Rosuvastatin Among High-Risk Patients with Dyslipidaemia","abstract":"<jats:p>Aim: The aim of this analysis was to compare the effectiveness of rosuvastatin in lowering cholesterol with that of atorvastatin in patients at high risk of dyslipidaemia. Place and Duration: In the Medicine department of Islam Medical College and Teaching Hospital Sialkot for six months duration from June 2021 to November 2021. Methods: This randomized, open-label study enrolled 90 patients with high-risk dyslipidaemia and diagnosed according to the international guidelines for the prevention of adult dyslipidaemia. These patients were randomized to rosuvastatin and atorvastatin to receive rosuvastatin 20 mg / day and atorvastatin 20 mg / day, respectively, for three months. In both groups, the efficacy of atorvastatin and rosuvastatin on the concentration of LDL-C, HDL-C, total cholesterol (TC) and triglycerides (TG) was assessed. In addition, the rates of achieving LDL-C or TC target levels were assessed in both groups. Results: Rosuvastatin caused a significantly greater reduction of LDL-C (43.2% and 38.1%, p &lt;0.05) and TC (34.8% Vs 28.1%, p &lt;0.05) than Atorvastatin. In addition, the percentage of subjects attaining the recommended target TC and LDL-C levels was higher in the group of rosuvastatin as compared to the atorvastatin group. Conclusions: In patients at high risk of hyperlipidemia, rosuvastatin has high efficacy in decreasing lipids than atorvastatin. Keywords: rosuvastatin, atorvastatin, dyslipidaemia, high-density lipoprotein, triglycerides.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":null,"openalex_id":"https://openalex.org/W4211137976","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.02229422,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":null,"oa_locations":[{"url":"https://pjmhsonline.com/2022/jan/683.pdf","host_type":"journal"},{"url":"https://pjmhsonline.com/2022/jan/683.pdf","host_type":"publisher"},{"url":"https://doi.org/10.53350/pjmhs22161683","host_type":"journal"}],"fields_of_study":["Lipoproteins and Cardiovascular Health","Cancer, Lipids, and Metabolism"],"mesh_terms":[],"keywords":["Rosuvastatin","Atorvastatin","Medicine","Internal medicine","Hyperlipidemia","Randomized controlled trial","Statin","Gastroenterology","Endocrinology"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T12:24:41.524807Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}